NASDAQ:RAIN
Rain Therapeutics Inc.
- Stock
locale
United States
market
STOCKSindustry
Biotechnologywebsite
www.rainthera.comipo date
Apr 23, 2021
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for lipos...Show More
Earnings
Earnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus